Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks

Cancer Biology and Medicine

Volumn 10, Issue 4, 2013, Pages 192-205

  Gomez, German G ^a   Wykosky, Jill ^a   Zanca, Ciro ^a   Furnari, Frank B ^a   Cavenee, Webster K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidermal growth factor receptor; MicroRNA; Therapeutic resistance; Tyrosine kinase inhibitors

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LET 7 PROTEIN; LIGAND; MICRORNA; MICRORNA 21; MICRORNA 34; MICRORNA 7; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RESISTANCE; CELLULAR DISTRIBUTION; DRUG MECHANISM; ENZYME ACTIVATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84891340358     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2013.04.003     Document Type: Review

References (155)

1. Huang P H, Xu A M, White F M. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009;2: re6.
2. Taylor T E, Furnari F B, Cavenee W K. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 2012;12:197-209.
3. Wheeler D L, Dunn E F, Harari P M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
4. Dunn G P, Rinne M L, Wykosky J, Genovese G, Quayle S N, Dunn I F, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012;26:756-784.
5. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials 2013;34:8690-8707.
6. Wykosky J, Fenton T, Furnari F, Cavenee W K. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer 2011;30:5-12.
7. Calin G A, Croce C M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
8. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979;48:193-216.
9. Nishikawa R, Ji X D, Harmon R C, Lazar C S, Gill G N, Cavenee W K, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-7731.
10. Petrides P E, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 1990;50:3934-3939.
11. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res 1988;48:6753-6757.
12. Wikstrand C J, McLendon R E, Friedman A H, Bigner D D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57:4130-4140.
13. Lee J C, Vivanco I, Beroukhim R, Huang J H, Feng W L, DeBiasi R M, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006;3:e485.
14. Hurtt M R, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 1992;51:84-90.
15. Jaros E, Perry R H, Adam L, Kelly P J, Crawford P J, Kalbag R M, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992;66:373-385.
16. Lenz H J, Van Cutsem E, Khambata-Ford S, Mayer R J, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921.
17. Lièvre A, Bachet J B, Le Corre D, Boige V, Landi B, Emile J F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
18. Schlegel J, Stumm G, Brändle K, Merdes A, Mechtersheimer G, Hynes N E, et al. Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol 1994;22:201-207.
19. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-223; discussion 23-24.
20. Gan H K, Kaye A H, Luwor R B. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16:748-754.
21. Nagane M, Levitzki A, Gazit A, Cavenee W K, Huang H J. Drug resistance of human glioblastoma cells conferred by a tumorspecific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 1998;95:5724-5729.
22. Jones T S, Holland E C. Molecular pathogenesis of malignant glial tumors. Toxicol Pathol 2011;39:158-166.
23. Frederick L, Wang X Y, Eley G, James C D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-1387.
24. Jänne P A, Engelman J A, Johnson B E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234.
25. Sharma S V, Bell D W, Settleman J, Haber D A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
26. Lynch T J, Bell D W, Sordella R, Gurubhagavatula S, Okimoto R A, Brannigan B W, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
27. Paez J G, Jänne P A, Lee J C, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
28. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
29. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee W K, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 2004;21:53-56.
30. Inda M M, Bonavia R, Mukasa A, Narita Y, Sah D W, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731-1745.
31. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A 2007;104:13092-13097.
32. Lax I, Fischer R, Ng C, Segre J, Ullrich A, Givol D, et al. Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. Cell Regul 1991;2:337-345.
33. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37 Suppl 4:S3-8.
34. Wong L, Deb T B, Thompson S A, Wells A, Johnson G R. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. J Biol Chem 1999;274:8900-8909.
35. Rusch V, Klimstra D, Venkatraman E, Pisters P W, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-522.
36. Vermi W, Giurisato E, Lonardi S, Balzarini P, Rossi E, Medicina D, et al. Ligand-Dependent Activation of EGFR in Follicular Dendritic Cells Sarcoma is Sustained by Local Production of Cognate Ligands. Clin Cancer Res 2013;19:5027-5038.
37. Erjala K, Sundvall M, Junttila T T, Zhang N, Savisalo M, Mali P, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-4111.
38. Cao H, Lei Z M, Bian L, Rao C V. Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology 1995;136:3163-3172.
39. Lin S Y, Makino K, Xia W, Matin A, Wen Y, Kwong K Y, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-808.
40. Lo H W, Hsu S C, Hung M C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 2006;95:211-218.
41. Lo H W, Xia W, Wei Y, Ali-Seyed M, Huang S F, Hung M C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005;65:338-348.
42. Marti U, Burwen S J, Wells A, Barker M E, Huling S, Feren A M, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991;13:15-20.
43. Psyrri A, Yu Z, Weinberger P M, Sasaki C, Haffty B, Camp R, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11:5856-5862.
44. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu Y L, et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009;48:610-617.
45. Lo H W, Hung M C. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006;94:184-188.
46. Wang S C, Hung M C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res 2009;15:6484-6489.
47. Wang S C, Nakajima Y, Yu Y L, Xia W, Chen C T, Yang C C, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 2006;8:1359-1368.
48. Boerner J L, Demory M L, Silva C, Parsons S J. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 2004;24:7059-7071.
49. Li S, Schmitz K R, Jeffrey P D, Wiltzius J J, Kussie P, Ferguson K M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-311.
50. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 2004;351:337-345.
51. Vermorken J B, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med 2008;359:1116-1127.
52. Yang X D, Jia X C, Corvalan J R, Wang P, Davis C G, Jakobovits A. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant hemotherapy. Cancer Res 1999;59:1236-1243.
53. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. J Clin Oncol 2007;25:1658-1664.
54. Mishima K, Johns T G, Luwor R B, Scott A M, Stockert E, Jungbluth A A, et al. Growth Suppression of Intracranial Xenografted Glioblastomas Overexpressing Mutant Epidermal Growth Factor Receptors by Systemic Administration of Monoclonal Antibody (mAb) 806, a Novel Monoclonal Antibody Directed to the Receptor. Cancer Res 2001;61:5349-5354.
55. Scott A M, Lee F T, Tebbutt N, Herbertson R, Gill S S, Liu Z, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A. 2007;104:4071-4076.
56. Jaramillo M L, Leon Z, Grothe S, Paul-Roc B, Abulrob A, O'Connor McCourt M. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 2006;312:2778-2790.
57. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines. Clin Cancer Res 2007;13:1552-1561.
58. Yu J S, Wheeler C J, Zeltzer P M, Ying H, Finger D N, Lee P K, et al. Vaccination of Malignant Glioma Patients with Peptide-pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-cell Infiltration. Cancer Res 2001;61:842-847.
59. Del Vecchio C A, Li G, Wong A J. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines 2012;11:133-144.
60. Zhou X, Li J, Wang Z, Chen Z, Qiu J, Zhang Y, et al. Cellular immunotherapy for carcinoma using genetically modified EGFRspecific T lymphocytes. Neoplasia 2013;15:544-553.
61. El-Rayes B F, LoRusso P M. Targeting the epidermal growth factor receptor. Br J Cancer 2004;91:418-424.
62. Available online: http://www.fda.gov/ Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm (Accessed 12 Sept 2013).
63. Available online: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/RecentlyApprovedDevices/ucm360819 (Accessed 12 Sept 2013).
64. Arteaga C L. Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression? Oncologist 2002;7:31-39.
65. Amado R G, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D J, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
66. Sampson J H, Heimberger A B, Archer G E, Aldape K D, Friedman A H, Friedman H S, et al. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 2010;28:4722-4729.
67. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, et al. Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non? ÄìSmall Cell Lung Cancer and Acquired Resistance to Gefitinib. Clin Cancer Res 2006;12:5764-5769.
68. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-4711.
69. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, et al. LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. J Clin Oncol 2013;31:3335-3341.
70. Bean J, Brennan C, Shih J Y, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-20937.
71. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. Cancer Research 2008;68:9479-9487.
72. Engelman J A, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J O, et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 2007;316:1039-1043.
73. Wheeler D L, Huang S, Kruser T J, Nechrebecki M M, Armstrong E A, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-3956.
74. Byers L A, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clin Cancer Res 2013;19:279-290.
75. Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 2013;32:3846-3856.
76. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology 2010;11:753-762.
77. Mellinghoff I K, Wang M Y, Vivanco I, Haas-Kogan D A, Zhu S, Dia E Q, et al. Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. N Engl J Med 2005;353:2012-2024.
78. Mellinghoff I K, Cloughesy T F, Mischel P S. PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clin Cancer Res 2007;13:378-381.
79. Fenton T R, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A 2012;109:14164-14169.
80. Stommel J M, Kimmelman A C, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science 2007;318:287-290.
81. Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A 2013;110:4339-4344.
82. Lee R C, Feinbaum R L, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854.
83. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-858.
84. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. RNA 2003;9:175-179.
85. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12:735-739.
86. Vaz C, Ahmad H M, Sharma P, Gupta R, Kumar L, Kulshreshtha R, et al. Analysis of microRNA transcriptome by deep sequencing of small RNA libraries of peripheral blood. BMC Genomics 2010;11:288.
87. Han J, Lee Y, Yeom K H, Kim Y K, Jin H, Kim V N. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004;18:3016-3027.
88. Yi R, Qin Y, Macara I G, Cullen B R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17:3011-3016.
89. Grishok A, Pasquinelli A E, Conte D, Li N, Parrish S, Ha I, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 2001;106:23-34.
90. Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 2002;16:720-728.
91. Okamura K, Hagen J W, Duan H, Tyler D M, Lai E C. The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell 2007;130:89-100.
92. Sibley C R, Seow Y, Saayman S, Dijkstra K K, El Andaloussi S, Weinberg M S, et al. The biogenesis and characterization of mammalian microRNAs of mirtron origin. Nucleic Acids Res 2012;40:438-448.
93. Calin G A, Dumitru C D, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-15529.
94. Lujambio A, Calin G A, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105:13556-13561.
95. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010:247-256.
96. Lee E J, Baek M, Gusev Y, Brackett D J, Nuovo G J, Schmittgen T D. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 2008;14:35-42.
97. Suzuki H I, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009;460:529-533.
98. Seike M, Goto A, Okano T, Bowman E D, Schetter A J, Horikawa I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009;106:12085-12090.
99. Huang T H, Wu F, Loeb G B, Hsu R, Heidersbach A, Brincat A, et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem 2009;284:18515-18524.
100. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y J, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011;18:74-82.
101. Talotta F, Cimmino A, Matarazzo M R, Casalino L, De Vita G, D'Esposito M, et al. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2009;28:73-84.
102. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 2010;90:144-155.
103. Hatley M E, Patrick D M, Garcia M R, Richardson J A, Bassel-Duby R, van Rooij E, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010;18:282-293.
104. Ma X, Kumar M, Choudhury S N, Becker Buscaglia L E, Barker J R, Kanakamedala K, et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci U S A 2011;108:10144-10149.
105. Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, et al. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Cancer Prev Res (Phila) 2012;5:248-259.
106. Chang T C, Zeitels L R, Hwang H W, Chivukula R R, Wentzel E A, Dews M, et al. Lin-28B transactivation is necessary for Mycmediated let-7 repression and proliferation. Proc Natl Acad Sci U S A 2009;106:3384-3389.
107. Viswanathan S R, Daley G Q, Gregory R I. Selective blockade of microRNA processing by Lin28. Science 2008;320:97-100.
108. Viswanathan S R, Powers J T, Einhorn W, Hoshida Y, Ng T L, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009;41:843-848.
109. Johnson S M, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647.
110. Li X, Carthew R W. A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the Drosophila eye. Cell 2005;123:1267-1277.
111. Chou Y T, Lin H H, Lien Y C, Wang Y H, Hong C F, Kao Y R, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010;70:8822-8831.
112. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008;68:3566-3572.
113. Webster R J, Giles K M, Price K J, Zhang P M, Mattick J S, Leedman P J. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009;284:5731-5741.
114. Lee S T, Chu K, Oh H J, Im W S, Lim J Y, Kim S K, et al. Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 2011;102:19-24.
115. Kalinowski F C, Giles K M, Candy P A, Ali A, Ganda C, Epis M R, et al. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PLoS One 2012;7:e47067.
116. Krichevsky A M, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009;13:39-53.
117. Chan J A, Krichevsky A M, Kosik K S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029-6033.
118. Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A, Bello A M, et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 2011;30:275-286.
119. Loayza-Puch F, Yoshida Y, Matsuzaki T, Takahashi C, Kitayama H, Noda M. Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs. Oncogene 2010;29:2638-2648.
120. Gwak H S, Kim T H, Jo G H, Kim Y J, Kwak H J, Kim J H, et al. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One 2012;7:e47449.
121. Hummel R, Hussey D J, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010;46:298-311.
122. Cufí S, Bonavia R, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, et al. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci Rep 2013;3:2459.
123. Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012;7:e39520.
124. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011;286:19127-19137.
125. Pasquinelli A E, Reinhart B J, Slack F, Martindale M Q, Kuroda M I, Maller B, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000;408:86-89.
126. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-3756.
127. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-1123.
128. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 2012;18:529-537.
129. Oh J S, Kim J J, Byun J Y, Kim I A. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 2010;76:5-8.
130. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012;17:823-829.
131. Xia X M, Jin W Y, Shi R Z, Zhang Y F, Chen J. Clinical significance and the correlation of expression between Let-7 and K-ras in nonsmall cell lung cancer. Oncol Lett 2010;1:1045-1047.
132. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68:8535-8540.
133. Christensen B C, Moyer B J, Avissar M, Ouellet L G, Plaza S L, McClean M D, et al. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009;30:1003-1007.
134. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximabirinotecan. Pharmacogenomics J 2010;10:458-464.
135. Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics 2013;23:142-147.
136. Petriella D, Galetta D, Rubini V, Savino E, Paradiso A, Simone G, et al. Molecular profiling of thin-prep FNA samples in assisting clinical management of non-small-cell lung cancer. Mol Biotechnol 2013;54:913-919.
137. Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, et al. Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol 2013. [Epub ahead of print].
138. Croce C M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-714.
139. Fang Y, Xue J L, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012;55:1852-1862.
140. Giles K M, Brown R A, Epis M R, Kalinowski F C, Leedman P J. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun 2013;430:706-710.
141. Saydam O, Senol O, Würdinger T, Mizrak A, Ozdener G B, Stemmer-Rachamimov A O, et al. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 2011;71:852-861.
142. Lee K M, Choi E J, Kim I A. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 2011;101:171-176.
143. Levine A J, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006;13:1027-1036.
144. He L, He X, Lim L P, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-1134.
145. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26:731-743.
146. Zenz T, Mohr J, Eldering E, Kater A P, Bühler A, Kienle D, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009;113:3801-3808.
147. Hünten S, Siemens H, Kaller M, Hermeking H. The p53/microRNA network in cancer: experimental and bioinformatics approaches. Adv Exp Med Biol 2013;774:77-101.
148. Corney D C, Hwang C I, Matoso A, Vogt M, Flesken-Nikitin A, Godwin A K, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010;16:1119-1128.
149. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009;69:7569-7576.
150. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010;9:1031-1036.
151. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008;68:10128-10136.
152. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 2008;5:209-217.
153. Hwang C I, Matoso A, Corney D C, Flesken-Nikitin A, Körner S, Wang W, et al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A 2011;108:14240-14245.
154. Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One 2013;8:e61054.
155. Kasinski A L, Slack F J. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012;72:5576-5587.